PT-141 (Bremelanotide): Mechanism & Research Use

PT-141 (bremelanotide) is a cyclic heptapeptide analogue of alpha-MSH and a non-selective melanocortin receptor agonist (reported order of potency MC1R, MC4R, MC3R, MC5R). It is most studied at MC4R and MC3R in receptor-signalling research. It is the compound marketed under the brand name Vyleesi; the material sold by Milo-Lab is unbranded research-grade material for laboratory use.

What Is PT-141?

PT-141 is a synthetic, cyclic analogue of the endogenous melanocortin peptide alpha-MSH. Like alpha-MSH, it binds members of the melanocortin receptor family, which are G-protein-coupled receptors. It is non-selective across the family and is most studied at MC4R and MC3R.

Full mechanism detail and citations are available on the PT-141 product page.

MC3R and MC4R: Different Receptor Subtypes

MC4R is the receptor subtype most studied in connection with PT-141 and is expressed in the central nervous system, including the hypothalamus. MC3R, expressed more in limbic circuitry, is less well characterised than MC4R. Differences in subtype distribution and signalling between MC3R and MC4R are a recurring topic in melanocortin receptor research.

Storage

PT-141 is supplied as a lyophilised powder.

Lyophilised vials: store at -20°C, protected from light.

Milo-Lab supplies PT-141 as a 10mg vial, with a certificate of analysis per batch.

Other reproductive-axis compounds (kisspeptin, oxytocin) are listed in the catalogue category.

Research Use Only

PT-141 (bremelanotide) supplied by Milo-Lab is sold strictly for laboratory research use, as unbranded research-grade material for qualified researchers. Milo-Lab gives no use or dosing advice, and nothing in this article is medical advice.

See the full PT-141 profile for pack details, FAQs and complete study citations. For research purposes only. Not for human consumption.